PULMOZYME Drug Insight and Market Forecast - 2032

This “PULMOZYME Drug Insight and Market Forecast - 2032” report provides comprehensive insights about PULMOZYME for Cystic Fibrosis in the six major markets. A detailed picture of the PULMOZYME for cystic fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PULMOZYME for cystic fibrosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PULMOZYME market forecast analysis for cystic fibrosis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in cystic fibrosis.

Drug Summary

PULMOZYME (dornase alfa) is a recombinant human deoxyribonuclease I (rhDNase) an enzyme which selectively cleaves DNA. The protein is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing DNA encoding for the native human protein, deoxyribonuclease I (DNase). The product is purified by column chromatography and tangential flow filtration. The purified glycoprotein contains 260 amino acids with an approximate molecular weight of 37,000 daltons. The primary amino acid sequence is identical to that of the native human enzyme.

Mechanism of Action
PULMOZYME is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the PULMOZYME description, mechanism of action, dosage and administration, research and development activities in cystic fibrosis.
• Elaborated details on PULMOZYME regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PULMOZYME research and development activities in cystic fibrosis across the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report also covers the patents information with expiry timeline around PULMOZYME.
• The report contains forecasted sales of PULMOZYME for cystic fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for cystic fibrosis.
• The report also features the SWOT analysis with analyst views for PULMOZYME in cystic fibrosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PULMOZYME Analytical Perspective

In-depth PULMOZYME Market Assessment

This report provides a detailed market assessment of PULMOZYME for cystic fibrosis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

PULMOZYME Clinical Assessment

The report provides the clinical trials information of PULMOZYME for cystic fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for cystic fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PULMOZYME dominance.
• Other emerging products for cystic fibrosis are expected to give tough market competition to PULMOZYME and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PULMOZYME in cystic fibrosis.
• This in-depth analysis of the forecasted sales data of PULMOZYME from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PULMOZYME in cystic fibrosis.

Key Questions

• What is the product type, route of administration and mechanism of action of PULMOZYME?
• What is the clinical trial status of the study related to PULMOZYME in cystic fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PULMOZYME development?
• What are the key designations that have been granted to PULMOZYME for cystic fibrosis?
• What is the forecasted market scenario of PULMOZYME for cystic fibrosis?
• What are the forecasted sales of PULMOZYME in the six major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What are the other emerging products available and how are these giving competition to PULMOZYME for cystic fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of cystic fibrosis?

This product will be delivered within 2 business days.